Health ❯ Healthcare ❯ Medical Treatments

Oncology

Lung Cancer Multiple Myeloma Glioma Bladder Cancer Non-Small Cell Lung Cancer Melanoma Therapy Chronic Myeloid Leukemia Small Cell Lung Cancer Breast Cancer Desmoid Tumors

FDA Accepts Roche’s Tecentriq for Priority Review in dMMR Stage III Colon Cancer

Approval by October 9, 2026 would establish the first immunotherapy-based adjuvant option for patients with dMMR/MSI-H stage III colon cancer.

FDA Approves Belzutifan With Pembrolizumab as Adjuvant Therapy for Clear Cell Kidney Cancer

FDA Approves Nivolumab Plus AVD as First-Line Therapy for Advanced Hodgkin Lymphoma

FDA Clears Enhertu-Perjeta Combo for First-Line HER2-Positive Metastatic Breast Cancer

Vaccimel, Argentina's Melanoma Immunotherapy, Enters Commercial Use

FDA Approves Perioperative Keytruda–Padcev for Cisplatin‑Ineligible Muscle‑Invasive Bladder Cancer

FDA Approves Komzifti, First Menin Inhibitor for Relapsed NPM1‑Mutant AML

FDA Approves Darzalex Faspro as First Therapy for High-Risk Smoldering Multiple Myeloma

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC

European Commission Approves Voranigo for IDH-Mutant Grade 2 Glioma

FDA Approves First Systemic Therapy for H3 K27M-Mutant Diffuse Midline Glioma

LUT014 Gel Shows Promise in Reducing Severe Rash from Colorectal Cancer Therapy